BriaCell Therapeutics Corp. reported unprecedented activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies at the 2023 Society for Immunotherapy of Cancer (SITC) annual meeting. These novel immunotherapies have been shown to activate the immune system through multiple mechanisms including adaptive responses of naïve (resting) T cells and innate responses of dendritic cells and natural killer (NK) cells leading to enhanced clinical efficacy and prevention of immune escape.

BriaCell?s current lead candidate, Bria-IMT?, has enhanced efficacy in human leucocyte (HLA) matched patients (LINK) and led to the development of Bria-OTS?, an off the shelf personalized immunotherapy providing HAL matched targeting to >99% of the US population. BriaCell?s poster presentation highlights the development details and activities of BriaCell?s next generation off-the-shelf personalized immunotherapies for breast and prostate cancers. Abstract Title: Development and Mechanism of Action of a Novel Cellular Immunotherapeutic Platform for the Treatment of Advanced Solid Tumors Abstract Number: 419 Location:San Diego Convention Center, San Diego, CA Session Date and Time: Friday November 3, 20239:00 AM - 6:00 PM Immune system activation by BriaCell?s next generation personalized off-the-shelf immunotherapy BriaCell has developed next generation, cell-based, personalized immunotherapies, Bria-OTS+?

(for breast cancer) and Bria-PROS+? (for prostate cancer) that produce immune system activating molecules e.g., antigen presenting cell components and granulocyte macrophage colony stimulating factor (GM-CSF), as well as newly added immune system activating factors such as costimulatory molecules and cytokines. Potential advantages of BriaCell?s next generation personalized off-the-shelf immunotherapies include: Precision Therapy: Bria-OTS+?

cell lines are precisely matched to individual patients based on their HLA antigens, encompassing over 99% of the U.S. population. This personalized approach would provide optimal compatibility and effectiveness of cancer immunotherapy. Favorable Safety Profile: Bria-OTS+?

therapies are expected to avoid the severe and potentially life-threatening adverse events often associated with current treatments. Rapid, Cost-Effective Treatments: BriaCell OTS+? therapies are produced for ?off-the-shelf?

use. This novel approach allows for the immediate administration of immunotherapy following standard patient HLA genotyping. This streamlined process eliminates individualized manufacturing requirements and may offer efficient and cost-effective personalized treatment options to cancer patients in need.

Potent Immune System Activation: BriaCell?s data has shown unprecedented broad immune system responses to the next generation immunotherapies compared with those of the earlier formulation. Additionally, findings confirmed that both Bria-OTS+? and Bria-PROS+?activate multiple components of the immune system through direct activation of naïve (resting) T- cells as well as activation of Natural killer (NK) cells via production of immune activating molecules including CD86 (a co-stimulatory molecule).

Platform Technology: These findings support further development of BriaCell?s platform of next-generation cancer immunotherapies for multiple cancer types, focusing initially on breast, and prostate cancers. In summary, BriaCell?s novel next generation personalized immunotherapy delivers broad immune responses against various solid tumor models via multiple immune activating mechanisms. BriaCell?s cell-based immunotherapies may offer superior efficacy in addition to favorable safety profiles in cancer patients. Importantly, the off-the-shelf (i.e., premanufactured) nature of immunotherapy may shorten the time to receive cancer treatment, and perhaps prevent disease progression in cancer patients.

BriaCell expects the administration of personalized BRIA-OTS+? and BRIA-PROS+? immunotherapies, following a rapid and routine HLA test, to provide safe and effective treatment options for cancer patients.

These findings support BriaCell?s strategy to further develop this approach as a platform technology with broad applications for multiple cancers.